<DOC>
	<DOCNO>NCT02838355</DOCNO>
	<brief_summary>The purpose study explore End Tidal Carbon Dioxide monitoring via nasal cannula ( ETCO2-NC ) device may allow early detection respiratory complication . This device detect amount carbon dioxide exhale breath may better predict high level traditional monitoring . This may reduce number severity respiratory issue . A convenience sample 60 participant either schedule continuous flow leave ventricular assist device ( CF-LVAD ) implant readmitted ICU CF-LVAD recruit randomize usual care usual care plus ETCO2-NC throughout stay ICU .</brief_summary>
	<brief_title>Employing End Tidal Capnography Continuous Flow Ventricular Assist Device Patients</brief_title>
	<detailed_description>The purpose proposal explore relationship End Tidal Carbon Dioxide ( ETCO2 ) via nasal cannula ( ETCO2-NC ) routinely measure physiologic participant report parameter extubated participant receive continuous flow leave ventricular assist device ( CF-LVAD ) , determine addition ETCO2-NC monitoring usual care associate decrease incidence severity respiratory issue . A convenience sample 60 participant either schedule mechanical circulatory support device ( MCSD ) implant readmitted intensive care unit ( ICU ) CF-LVAD recruit randomize usual care usual care plus ETCO2-NC throughout stay ICU . Investigators seek examine relationship ETCO2-NC traditional physiologic measure , clinical assessment , participant report symptoms person CF-LVAD . Additionally , study intend compare respiratory outcome extubated person CF-LVAD randomize usual care receive usual care plus ETCO2- NC .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>Scheduled mechanical circulatory support device ( MCSD ) implant readmitted intensive care unit ( ICU ) continuous flow leave ventricular assist device ( CFLVAD ) New York Heart Association ( NYHA ) functional class III IV Ability read , write , speak English Requiring mechanical ventilation active phase trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>